>Sawyer Groothuis
Related?
ADAM GROOTHUIS NPI 1417544198
Technician, Other -Biomedical Engineeringin Swampscott, MA
>https://npiprofile.com/npi/1417544198
>Related?
> ADAM GROOTHUIS NPI 1417544198
>Technician, Other -Biomedical Engineeringin Swampscott, MA
Current institution
Cardiovalve Ltd
Therapy Development
Current position
Vice President
Co-authors
Top co-authors
Elazer Edelman
MIT
Artur Baszko
Poznan University of Medical Sciences
Martin Ehrbar
University of Zurich
David Ettenson
David Ettenson Consulting
Yiannis S Chatzizisis
Brigham and Women's Hospital
All co-authors (50)
>https://www.researchgate.net/profile/Adam-Groothuis-2
Adam Groothuis' Work History and Education
Cardiovalve
VP Therapy Development
2019 - Present
MIT
Research Associate
1998 - 2012 • 14 years
Brigham and Women's Hospital
Associate Director ECI Lab
2002 - 2006 • 4 years
NIH
Biologist
1997 - 1998 • 10 months
>https://www.apollo.io/people/Adam/Groothuis/54a5bbbb746869320940fba3
New Brigham Center for Transgender Health Aims to Lead the Field
Progress pride flag on flagpole flying in sky
This year, Brigham and Women’s Hospital launched an academic center focused on the healthcare needs of transgender and gender-diverse (TGD) people. The Brigham Center for Transgender Health features a multidisciplinary team committed to supporting TGD patients at every step of their journey.
Consolidating and Coordinating Gender-affirming Care
The formation of the center is an attempt to consolidate and coordinate the provision of gender-affirming care at the Brigham under one roof. Plastic surgery, endocrinology, urology, gynecology, otolaryngology, dermatology, primary care, voice therapy, physical therapy, and mental health are among the many disciplines represented, allowing the center to offer a full range of medical and surgical care.
“The field of gender-affirming care has advanced a lot from where it was even five years ago,” Dr. Coon says. “Continuing to raise the bar will require multiple specialties bringing all they know to the table. Having so many people at the Brigham who are interested and involved in this center is one of the key factors that will make us a leader going forward.”
>https://www.brighamhealthonamission.org/2022/06/22/new-brigham-center-for-transgender-health-aims-to-lead-the-field/
>Current institution
>Cardiovalve Ltd
> Therapy Development
>Current position
> Vice President
Cardiovalve
industryMedical devices
publicityPublic company
foundedFounded in 2009
phone+97286-0571-8675-9022
locationOr Yehuda, Tel AvivDistrict
websitevenusmedtech.com
linkedin/cardiovalve
EmployeesEmployees
TechnologiesTechnologies
AlumniAlumni
Cardiovalve information
Cardiovalve is a pioneer in the field of transcatheter valve replacement. The company has been part of Venus Medtech (HKG:2500) since 2022. We help patients suffering from heart valve disease to access innovative solutions. Our products empower physicians to offer their patients an improved quality of life without the need for open-heart surgery. We build our solutions from the bottom up for transfemoral/transseptal delivery, accessing the heart through the femoral vein. This unique approach offers significant benefits, including a short implant profile (mimics a surgical-like design), and minimal protrusion to the left ventricle, minimizing interference in the cardiac blood flow and increasing safety. Cardiovalve's objective is to seek approvals in the EU, China, and North America for its system after final proof of the safety and performance of its system in clinical studies.Learn more about Cardiovalve at www.cardiovalve.com.
Cardiovalve industries
>So I did some research and the dude's name who smoked this chick in the face is Sawyer Groothuis.
>Biomedical Engineeringin Swampscott, MA
>Cardiovalve Ltd
> Therapy Development
>Current position
> Vice President
>locationOr Yehuda, Tel AvivD
Noah GroothuisUnited States
September 2003 - February 2007
Sales Representative at Forest Laboratories
Pharmaceuticals
Experience
Forest Laboratories now Allergan February 2007 - Present
Bank of Hawaii September 2003 - February 2007
United States Peace Corps January 1998 - January 2000
Gladstone's Restaurant - Universal Studios Hollywood January 1997 - January 1998
U.S. Mortgage & Acceptance January 1996 - January 1997
Affiliated Funding Corporation January 1994 - January 1996
Skills
Customer Relations, Account Management, Lead Generation, People Skills, Sales Process, Loans, Marketing, Sales, Leadership, Analysis
Education
Chaminade University 2001 — 2003
Master of Business Administration (MBA), Entrepreneurship/Entrepreneurial Studies
University of Southern California 1987 — 1991
Bachelor of Fine Arts, Theatre Arts
>https://bearsofficialsstore.com/company/bank_of_hawaii/page5
>Sales Representative at Forest Laboratories
>Pharmaceuticals
>Experience
>Forest Laboratories now Allergan February 2007 - Present
Evergreen Forest??
Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis (now Allergan).
History
The company was founded by Hans Lowey in 1956 as a small laboratory service company.[2]
In 1967, the company became a public company via an initial public offering.[3]
Ten years later, Howard Solomon became the chief executive officer of the company.[3]
In 1984, the company acquired O'Neal Jones & Feldman for $8.8 million after a federal investigation resulted in one of its drugs being recalled.[4][2]
On July 17, 1998, the company received approval from the Food and Drug Administration for Celexa (Citalopram), an antidepressant.[5]
In 2000, the company cut ties with Warner-Lambert for the marketing of Celexa after Warner-Lambert was acquired by Pfizer.[6]
On August 16, 2002, the company received approval from the Food and Drug Administration for Lexapro (Escitalopram), an updated version of Celexa.[7]
In 2013, Solomon retired as chief executive officer of the company.[8]
In February 2014, the company acquired Aptalis for $2.9 billion.[9]
On July 1, 2014, the company was acquired by Actavis (now Allergan).[10] The sale of the company came after pressure from Carl Icahn, the largest shareholder.
Products
Some of the products Forest Laboratories marketed with its partners included:
AeroBid (flunisolide inhaler) for allergic rhinitis
Armour Thyroid (desiccated thyroid extract tablets) for hypothyroidism and pituitary Thyroid-stimulating hormone suppression
Bystolic (nebivolol) for hypertension
Campral (acamprosate) for maintenance of abstinence from alcohol in patients with alcohol dependence
Celexa (citalopram) for depression (developed by Lundbeck)
Cervidil (dinoprostone vaginal insert) for the initiation and/or continuation of cervical ripening in certain patients
Combunox (oxycodone/ibuprofen) for the short-term management of acute moderate-to-severe pain
Daliresp (roflumilast) for reduction of COPD exacerbations in patients with severe COPD
Fetzima (levomilnacipran extended release) for depression
Lexapro (escitalopram)for depression and generalized anxiety disorder (developed in cooperation with Lundbeck)
Levothroid (levothyroxine) for hypothyroidism and pituitaryTSH suppression
Linzess (linaclotide) for constipation-predominant irritable bowel syndrome and functional constipation
Monurol (fosfomycin) for certain urinary tract infections
Namenda and Namenda XR (memantine) for moderate-to-severe Alzheimer's disease
Savella (milnacipran) for fibromyalgia
Sudocrem medicated cream for irritant diaper dermatitis
Teflaro (ceftaroline fosamil) for acute bacterial skin and skin structure infections and community-acquired pneumonia caused by susceptible bacteria
Tiazac (diltiazem hydrochloride) for hypertension and chronic stable angina pectoris
Thyrolar (liotrix) for hypothyroidism and pituitary TSH suppression
Tudorza Pressair (aclidinium bromide inhalation powder) for COPD
Viibryd (vilazodone) for depression
Controversies
Illegal distribution and promotion of medicines
In September 2010, the company agreed to pay $313 million to resolve allegations of civil and criminal liability relating to felony, obstruction of justice, and theillegal distribution and promotion of pharmaceuticals, charges to which it pled guilty.One of the pharmaceutical-related charges was a misdemeanor charge of illegally promoting the Celexa and Lexapro for unapproved uses in treating pediatric depression. The other drug-related charge was a misdemeanor charge of distributing the unapproved drug Levothroid in violation of the Federal Food, Drug, and Cosmetic Act. Certain of the criminal activities were revealed with the help of whistleblowers, who received $14 million from the settlement.[11][12][13]
Forest Laboratories has been accused of using unlawful deals to prevent generic versions of its Alzheimer’s disease drug Namenda from entering the market.[14][15]
Tax avoidance via transfer pricing
In 2010, the company was criticized for legally moving its profits offshore via transfer pricing.[16]
>Noah Groothuis
>Noah Groothius could be a Hunter Bidan double.
>Interdasting.
>Forest Laboratories now Allergan February 2007 - Present
>for unapproved uses in treating pediatric depression.
Didn't expect this dig to be very interdasting, really
but
the coincidences just keep piling on
>(#2 for Swampscott) knocked the teeth out
>Biomedical Engineeringin Swampscott, MA
>Cardiovalve Ltd
> Therapy Development
>Current position
> Vice President
>locationOr Yehuda, Tel AvivD
>Forest Lab
>Honolulu Hawaii
>Scarlett
>Naaakasone
#2
knockout teeth
Big Pharma
Heart Valve
Swamp
Tel Aviv
Windsor
SampsonAve
SAMPSON